Rare variants in genes encoding structural myocyte contribute to a thickened ventricular septum in sudden death population without ventricular alterations.


Journal

Forensic science international. Genetics
ISSN: 1878-0326
Titre abrégé: Forensic Sci Int Genet
Pays: Netherlands
ID NLM: 101317016

Informations de publication

Date de publication:
05 2022
Historique:
received: 29 10 2021
revised: 08 03 2022
accepted: 12 03 2022
pubmed: 23 3 2022
medline: 6 4 2022
entrez: 22 3 2022
Statut: ppublish

Résumé

Unexpected cardiac deaths are a current challenge to healthcare systems. In adults, coronary artery disease and acquired cardiomyopathies are the most frequent causes of sudden cardiac death while in younger than 35 years old, the main cause is represented by non-ischemic diseases, usually inherited. Nowadays, around 10%-15% of unexpected deaths remain without a definite cause of decease after a complete autopsy, then classified as deaths potentially due to an inherited arrhythmia. Discrete abnormalities in some of the heart measures have been considered as potential predictors or risk factors for sudden cardiac death. However, role of non-benign genetic variants in these scattered heart alterations remains to be clarified, especially if variants are classified of ambiguous role. Clinicians usually only take into consideration pathogenic variants for decision-making. It is yet unclear what the role of VUS genetic variants in modifying the anatomical parameters of the heart. We hypothesize that some heart measures might be influenced by polygenic components as some variants may individually confer minor risk but may actually produce additive effects when combined with others. Our aim was to investigate whether carrying non-benign rare variants in genes related to inherited arrhythmias may contribute to scattered cardiac alterations in anatomical normal hearts. The study is composed by 761 samples collected from autopsies of SD suffered by adults from 18 to 50 years of age who occurred in Catalonia (Spain) in a 9-year period. Complete medico-legal autopsy was performed to determine the cause of death. Molecular autopsy was performed as part of our forensic protocol, including genes associated with inherited diseases.To evaluate the effect of genetic rare variants into hearts measures we performed a linear regression model and data were presented as regression. This study showed, for the first time, that rare variants, regardless of significance (pathogenic, probably pathogenic or uncertain significance), may contribute to interventricular septum width in the structurally normal heart. While the cohort is based on sudden death cases, further studies and case-control studies will be necessary to conclude that the genetic determinants of septal thickness contributes to sudden cardiac death. We conclude that non-benign rare variants contribute to modify scattered septum width in structural normal hearts, being a potential risk factor of arrhythmia in genetic harbors. These evidence support the current recommendation in forensic protocols of including histologic analysis of septum when inherited arrhythmogenic disease is suspicious cause of decease.

Identifiants

pubmed: 35316720
pii: S1872-4973(22)00029-1
doi: 10.1016/j.fsigen.2022.102688
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102688

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Mireia Alcalde (M)

Cardiovascular Genetics Center - Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain.

Laia Nogué-Navarro (L)

Faculty of Medicine, University of Vic - Central University of Catalonia (UVic-UCC), Can Baumann, 08500 Vic, Spain.

Coloma Tiron (C)

Cardiology Service, Hospital Dr. Josep Trueta, University of Girona, Girona, Spain; Centro Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid 28029, Spain.

Anna Fernandez-Falgueras (A)

Cardiology Service, Hospital Dr. Josep Trueta, University of Girona, Girona, Spain.

Anna Iglesias (A)

Cardiovascular Genetics Center - Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain.

Adria Simon (A)

Cardiovascular Genetics Center - Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain.

Maria Buxó (M)

Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain.

Alexandra Pérez-Serra (A)

Cardiovascular Genetics Center - Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain.

Marta Puigmulé (M)

Centro Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid 28029, Spain.

Laura López (L)

Cardiovascular Genetics Center - Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain.

Ferran Picó (F)

Cardiovascular Genetics Center - Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain.

Bernat Del Olmo (B)

Cardiovascular Genetics Center - Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain.

Monica Corona (M)

Cardiovascular Genetics Center - Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain.

Oscar Campuzano (O)

Cardiovascular Genetics Center - Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain; Cardiology Service, Hospital Dr. Josep Trueta, University of Girona, Girona, Spain; Medical Science Department, School of Medicine, University of Girona, Girona, Spain.

Sergio Moral (S)

Cardiology Service, Hospital Dr. Josep Trueta, University of Girona, Girona, Spain.

Josep Castella (J)

Forensic Pathology Service, Institut de Medicina Legal i Ciències Forenses de Catalunya (IMLCFC), Spain.

Mònica Coll (M)

Cardiovascular Genetics Center - Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain. Electronic address: mcoll@gencardio.com.

Ramon Brugada (R)

Cardiovascular Genetics Center - Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain; Cardiology Service, Hospital Dr. Josep Trueta, University of Girona, Girona, Spain; Centro Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid 28029, Spain; Institut d'Investigació Biomèdica de Girona (IdIBGi), 17190 Salt, Spain. Electronic address: ramon@brugada.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH